Genomictree Inc. (228760.KQ)

KRW 15420.0

(1.51%)

Market Cap (In KRW)

369.92 Billion

Revenue (In KRW)

3.41 Billion

Net Income (In KRW)

-8.75 Billion

Avg. Volume

139.33 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12010.0-27950.0
PE
-
EPS
-
Beta Value
-0.087
ISIN
KR7228760005
CUSIP
-
CIK
-
Shares
23990079.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sung-Whan An
Employee Count
-
Website
https://www.genomictree.com
Ipo Date
2017-04-05
Details
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers. Genomictree Inc. was founded in 2000 and is headquartered in Daejeon, South Korea.